The Caribbean nation has implemented a national intervention strategy, in which the need for the participation of all sectors of society is raised, the newspaper pointed out.

Reducing the stigma towards dementia, early diagnosis from the primary healthcare sector, and defending the elderly’s rights with cognitive impairment are emphasized, the source stresses.

Cuba is the fourth most aged nation in Latin America and more than 20 percent of its population is age 60 and older, the largest age group at risk of suffering from Alzheimer’s and other dementias.

According to Granma, Cuban scientists are working tirelessly to improve the patients’ quality of life hence they have developed molecule NeuroEPO, a drug developed by the Center for Molecular Immunology in partnership with other entities.

According to the 2019 Statistical Yearbook, the mortality rate in Cuba due to Alzheimer’s disease and other dementias was 5,97 deaths, with a rate of 45.4 per 100,000 inhabitants.

pgh/iff/mv/joe